On November 21, 2017 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) reported financial results for the third quarter 2017 (Press release, ImmunoCellular Therapeutics, NOV 21, 2017, View Source [SID1234522210]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: "As a result of the July financing and streamlining of operations, we have been able to significantly improve our financial condition and reduce our operating expenses. Our management team is focused on advancing our research-stage immuno-oncology programs and technologies, which we believe have potentially meaningful therapeutic and commercial value. At the same time, we are actively seeking to establish collaborations with academic or industry partners that have the resources to enable our clinical-stage programs to move forward. These steps are enabling us to focus resources on advancing our Stem-to-T-Cell program and continue operations at a significantly reduced burn rate and in a capital-efficient manner."
Dr. Gringeri continued: "We believe that our stem cell technology represents a major step forward in immuno-oncology approaches: that it represents clinically meaningful advantages over other novel immuno-oncology technologies; that it can be used in combination with other immuno-oncology therapeutic approaches; and that the potential return on investment for shifting our focus and dedicating resources to this program can create value for our company and for our shareholders. We remain focused on achieving our vision for our company: to develop immunotherapeutic solutions for intractable cancers, extending the lives of cancer patients, and providing hope for a potential cure. Our Stem-to-T-Cell program is at the research stage today, but we are developing it rapidly, and expect to achieve a number of meaningful milestones in the next 12 to 18 months."
Net loss for the quarter ended September 30, 2017, was $3.9 million compared to $4.8 million in the same period in 2016. Net loss available to common shareholders for the quarter ended September 30, 2017, was $6.1 million, or $0.40 per basic and diluted common share, compared to $4.8 million, or $1.58 per basic and diluted common share, in the same period in 2016. The 2017 net loss available to common shareholders includes the net loss of $3.9 million plus $1.6 million of deemed dividends and $600,000 of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. There were no similar charges during the quarter ended September 30, 2016.
For the quarter ended September 30, 2017, research and development expenses were $2.8 million compared to $4.6 million during the quarter ended September 30, 2016. The decrease primarily reflects the suspension of the phase 3 trial of ICT-107 in June 2017. During the third quarter of 2017, the Company incurred wind-down costs related to the trial, which are expected to taper in future quarters. General and administrative expenses for the quarter ended September 30, 2017, were $1.1 million compared to $900,000 in the same period in 2016. The additional expenses primarily reflect higher professional fees.
For the nine months ended September 30, 2017, the Company incurred a net loss of $13.9 million compared to $15.8 million in the same period in 2016. Net loss available to common shareholders for the nine months ended September 30, 2017 was $16.1 million, or $2.13 per basic and diluted share, compared to $15.8 million, or $6.19 per basic and diluted share, during the same period in 2016. The 2017 net loss available to common shareholders includes the net loss of $13.9 million plus $1.6 million of deemed dividends and $600,000 of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. There were no similar charges during the nine months ended September 30, 2016.
During the nine months ended September 30, 2017, the Company used $11.7 million of cash in operations compared to $16.1 million in the same period in 2016. During 2017, the Company applied certain vendor deposits against the termination invoices from some vendors that participated in the ICT-107 trial and delayed payments to certain other vendors. The Company is developing payment plans with its creditors.
In July 2017, ImmunoCellular completed a financing that provided $4.1 million in net proceeds from the sale of convertible preferred stock, with the potential to secure an additional $9 million in funding over the 12 months following the closing of the financing from the exercise of warrants to purchase preferred stock issued in the financing transaction. As part of the financing, the Company issued three warrant tranches of $3 million each with maturities in October 2017, January 2018 and July 2018. Through September 30, 2017, the Company received $2.2 million in net proceeds from the exercise of warrants. Subsequent to September 30, 2017, the Company received an additional $3.6 million of proceeds from the exercise of warrants. All of the warrants that expired in October 2017 were exercised. The proceeds from the financing are being used to move forward with a restructuring plan focused on winding down ICT-107 activities and advancing early-stage research programs while continuing to seek partnership opportunities for development-stage assets. As of September 30, 2017, the Company had $6.0 million in cash and 23,788,510 shares of common stock outstanding.
Conference Call and Webcast Today
ImmunoCellular plans to hold a conference call and webcast today, November 21, 2017, at 5:00 pm ET to review third quarter 2017 financial results and provide a business update. The call will be hosted by Anthony J. Gringeri, PhD, President and Chief Executive Officer.
LIVE CALL:
(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 3689426.
WEBCAST:
Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular’s website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.
The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.